score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.375	48.0	1.6e-05	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0				BRAF p.V600E (Missense)	1.0	MEL-IPI_Pat148	MEL-IPI_Pat148-Tumor-SM-5VWJQ	MEL-IPI_Pat148-Normal-SM-5VWI8
Investigate Actionability	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability	Ipilimumab	CTLA-4 inhibition	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498													0				 mutations per Mb		MEL-IPI_Pat148		
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q38*	0.8158	38.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0.0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				TP53 p.Q38* (Nonsense)		MEL-IPI_Pat148	MEL-IPI_Pat148-Tumor-SM-5VWJQ	MEL-IPI_Pat148-Normal-SM-5VWI8
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat148		
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.P92L	0.625	8.0	2.5e-05	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0				CHEK2 p.P92L (Missense)	0.0	MEL-IPI_Pat148	MEL-IPI_Pat148-Tumor-SM-5VWJQ	MEL-IPI_Pat148-Normal-SM-5VWI8
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Missense	p.N679D	0.2414	29.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677						0				BRCA2 p.N679D (Missense)		MEL-IPI_Pat148	MEL-IPI_Pat148-Tumor-SM-5VWJQ	MEL-IPI_Pat148-Normal-SM-5VWI8
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Nonsense	p.R580*	0.6522	23.0	2.5e-05	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475													0				ERBB3 p.R580* (Nonsense)		MEL-IPI_Pat148	MEL-IPI_Pat148-Tumor-SM-5VWJQ	MEL-IPI_Pat148-Normal-SM-5VWI8
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R31C	0.75	16.0	8e-06	0.0																					0				RUNX1T1 p.R31C (Missense)		MEL-IPI_Pat148	MEL-IPI_Pat148-Tumor-SM-5VWJQ	MEL-IPI_Pat148-Normal-SM-5VWI8
Biologically Relevant				Somatic Variant	RUNX1T1	Nonsense	p.W9*	0.7	30.0	0.0	0.0																					0				RUNX1T1 p.W9* (Nonsense)		MEL-IPI_Pat148	MEL-IPI_Pat148-Tumor-SM-5VWJQ	MEL-IPI_Pat148-Normal-SM-5VWI8
Biologically Relevant				Somatic Variant	RUNX1T1	Nonsense	p.W9*	0.6897	29.0	0.0	0.0																					0				RUNX1T1 p.W9* (Nonsense)		MEL-IPI_Pat148	MEL-IPI_Pat148-Tumor-SM-5VWJQ	MEL-IPI_Pat148-Normal-SM-5VWI8
Biologically Relevant				Copy Number	PIK3CB	Amplification				0.0	0.0																					0				PIK3CB Amplification		MEL-IPI_Pat148	MEL-IPI_Pat148-Tumor-SM-5VWJQ	
Biologically Relevant				Copy Number	DNMT3A	Deletion				0.0	0.0																					0				DNMT3A Deletion		MEL-IPI_Pat148	MEL-IPI_Pat148-Tumor-SM-5VWJQ	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion)		MEL-IPI_Pat148		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.73																									0				COSMIC Signature (version 2) 7 (73%)		MEL-IPI_Pat148		
